https://charts.traderzeitung.de/phases/US0373261058 string(1398) "{"isin":"US0373261058","name":"AN2 Therapeutics Inc","stock_id_xnas":22560313,"stock_id_xnys":null,"generated_at":"2026-09-24 01:31:00","days":[{"date":"2026-09-21","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":4.955,"close_at":"2026-09-21 21:59:00","complete":true,"perf_pct":null},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-09-22","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":4.84,"close_at":"2026-09-22 21:59:00","complete":true,"perf_pct":-2.3209},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-09-23","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":4.83,"close_at":"2026-09-23 21:59:00","complete":true,"perf_pct":-0.2066},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":false,"perf_pct":null}]}]}"

AN2 Therapeutics Aktie News & Nachrichten

[WKN: A3DKYC | Symbol: ANTX]

Realtimekurs

AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.

10J

Alles

Vorbörsliche Indikationen

Regulärer Handel

Nachbörslicher Handel

Artikel aus der Redaktion der Trader-Zeitung

Es konnten keine Nachrichten über AN2 Therapeutics gefunden werden.

AN2 Therapeutics Nachrichtenticker öffnen

MT Newswires 20.07.2026 12:46 Uhr

Guggenheim stuft AN2 Therapeutics mit Buy und einem Kursziel von $9 ein

MT Newswires 04.06.2026 14:05 Uhr

AN2 Therapeutics sagt, dass Medikament gegen Chagas-Krankheit positive präklinische und frühe Humandaten zeigt

08:04 AM EDT, 06/04/2026 (MT Newswires) -- AN2 Therapeutics (ANTX) sagte am Donnerstag, dass sein experimentelles Medikament AN2-502998 zur Behandlung